{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-053500","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2023-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.330475+00:00","generated_at":"2026-06-13T14:22:10.736837+00:00","sec_items":["1.01","2.03","3.02","5.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Allarity enters $350K secured note with 3i LP; amends preferred conversion price to $8.00","bullets":["Issued $350,000 secured promissory note to 3i LP, maturing July 31, 2023, at 5% annual interest.","Note secured by all company assets; proceeds for working capital and general corporate purposes.","Filed Second Certificate of Amendment reducing Series A Preferred conversion price from $0.75 to $8.00, reflecting 1:40 reverse stock split.","Outstanding obligations payable at next financing or convertible into 486 Series A Preferred shares if insufficient proceeds.","3i LP is the sole holder of Series A Preferred and has existing relationship with the company."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-053500","json":"https://secwatch.observer/filing/0001213900-23-053500.json","markdown":"https://secwatch.observer/filing/0001213900-23-053500.md","text":"https://secwatch.observer/filing/0001213900-23-053500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023053500/0001213900-23-053500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023053500/ea181165-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T14:22:10.736837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bbe180a851bb3bdd3615bd5234aa28255a8e7fd9","claim":"Allarity Therapeutics, Inc. incurred loan of $350,000 with 3i LP at 5% per annum maturing July 31, 2023.","evidence_excerpt":"Under the Purchase Agreement, the Company has authorized the sale and issuance of a secured promissory note in an aggregate principal amount of $350,000 to be issued at closing (the “Note”). The closing for the Note occurred on June 30, 2023 and the purchase price for the Note was paid in cash (“Closing”). The Note matures on July 31, 2023, carries an interest rate of at 5% per annum","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023053500/0001213900-23-053500-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"$350,000"},{"label":"Counterparty","value":"3i LP"},{"label":"Rate","value":"5% per annum"},{"label":"Maturity","value":"July 31, 2023"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"2e2b135dde34f15bff4dab0180e080c627fcb160","claim":"Allarity Therapeutics, Inc. entered into Secured Note Purchase Agreement with 3i LP valued at $350,000 (effective 2023-06-29).","evidence_excerpt":"On June 29, 2023, Allarity Therapeutics, Inc. (the “Company”) entered into a Secured Note Purchase Agreement (“Purchase Agreement”) with 3i LP, the sole holder of the Company’s outstanding shares of Series A Preferred Stock. Under the Purchase Agreement, the Company has authorized the sale and issuance of a secured promissory note in an aggregate principal amount of $350,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390023053500/0001213900-23-053500-index.htm","confidence":0.85,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"3i LP"},{"label":"Value","value":"$350,000"},{"label":"Effective","value":"2023-06-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}